Markets:

Overview

News

Currencies

International

Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

128.74 +4.62 (+3.72%)

Streaming Delayed Price Updated: 11:05 AM EST, Feb 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights ↗

January 28, 2025

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

Via Benzinga

NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. ↗

January 15, 2025

Investors seeking growth at a reasonable cost should explore NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).

Via Chartmill

Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Deserves Consideration as a Quality Investment. ↗

January 13, 2025

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Exhibits Quality Stock Traits. Here's Why.

Via Chartmill

Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. ↗

January 07, 2025

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a high growth stock and is consolidating.

Via Chartmill

NASDAQ:NBIX: good value for what you're paying. ↗

January 03, 2025

Investors should take notice ofNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—it offers a great deal for the fundamentals it presents.

Via Chartmill

Neurocrine Biosciences Stock Sees RS Rating Upgrade ↗

December 24, 2024

Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71.

Via Investor's Business Daily

What Analysts Are Saying About Neurocrine Biosciences Stock ↗

December 20, 2024

Via Benzinga

NASDAQ:NBIX qualifies as a high growth stock and is consolidating. ↗

November 28, 2024

Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. ↗

November 12, 2024

Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.

Via Chartmill

While growth is established for NASDAQ:NBIX, the stock's valuation remains reasonable. ↗

December 24, 2024

NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.

Via Chartmill

Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio? ↗

December 22, 2024

The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio?

Via Benzinga

Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential ↗

December 16, 2024

Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel approach to hormone regulation.

Via Benzinga

Neurocrine Wins FDA Approval For Genetic Disorder Drug ↗

December 13, 2024

The company can launch within a week, says Chief Executive Kyle Gano.

Via Investor's Business Daily

Screening For Black Friday Bargains In The Stock Market ↗

December 03, 2024

Via Benzinga

NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗

September 19, 2024

Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Standout High-Growth Stock in a Consolidation Phase.

Via Chartmill

Decoding 19 Analyst Evaluations For Neurocrine Biosciences ↗

September 09, 2024

Via Benzinga

NASDAQ:NBIX, a growth stock which is not overvalued. ↗

September 09, 2024

Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced.

Via Chartmill

For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering. ↗

December 03, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a growth opportunity that won't break the bank.

Via Chartmill

NASDAQ:NBIX stands out as a stock that provides good value for the fundamentals it showcases. ↗

November 19, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is an undervalued gem with solid fundamentals.

Via Chartmill

AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio ↗

November 12, 2024

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy.

Via Benzinga

In-Depth Examination Of 20 Analyst Recommendations For Neurocrine Biosciences ↗

October 29, 2024

Via Benzinga

NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. ↗

October 22, 2024

Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced.

Via Chartmill

NASDAQ:NBIX appears to be flying under the radar despite its strong fundamentals. ↗

October 21, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

October 11, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

Via Chartmill

Critical Insights From Neurocrine Biosciences Analyst Ratings: What You Need To Know ↗

October 04, 2024

Via Benzinga

"Rule Breaker Investing" Market Cap Game Show: Throwdowns & Long-Term Wins ↗

September 30, 2024

Motley Fool analysts Matt Argersinger and Yasser El-Shimy face off.

Via The Motley Fool

Despite its growth, NASDAQ:NBIX remains within the realm of affordability. ↗

September 30, 2024

In the world of growth stocks, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) shines as a value proposition.

Via Chartmill

For those who appreciate value investing, NASDAQ:NBIX is a compelling option with its solid fundamentals. ↗

September 26, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is probably undervalued for the fundamentals it is displaying.

Via Chartmill

Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint ↗

September 13, 2024

Neurocrine Biosciences announced that its ERUDITE Phase 2 trial for luvadaxistat failed to meet its primary endpoint in treating cognitive impairment in schizophrenia. The company will halt development...

Via Benzinga

Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio? ↗

September 08, 2024

10 worst performing large-cap stocks in August: Super Micro, Dollar General, Snap, PDD Holdings, Intel, Tencent Music, Gold Fields, Charles River, Moderna, Neurocrine Biosciences.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.